No connection

Search Results

CVRX vs LUCD

CVRX
CVRx, Inc.
BEARISH
Price
$8.37
Market Cap
$220.2M
Sector
Healthcare
AI Confidence
75%
LUCD
Lucid Diagnostics Inc.
BEARISH
Price
$1.28
Market Cap
$218.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
CVRX
--
LUCD
--
Forward P/E
CVRX
-4.71
LUCD
-7.11
P/B Ratio
CVRX
5.6
LUCD
-3.87
P/S Ratio
CVRX
3.89
LUCD
46.34
EV/EBITDA
CVRX
-3.86
LUCD
-5.38

Profitability

Gross Margin
CVRX
85.33%
LUCD
-41.73%
Operating Margin
CVRX
-69.8%
LUCD
-931.58%
Profit Margin
CVRX
-94.09%
LUCD
0.0%
ROE
CVRX
-96.59%
LUCD
-710.6%
ROA
CVRX
-26.9%
LUCD
-87.2%

Growth

Revenue Growth
CVRX
4.4%
LUCD
25.6%
Earnings Growth
CVRX
--
LUCD
--

Financial Health

Debt/Equity
CVRX
1.28
LUCD
2.36
Current Ratio
CVRX
7.63
LUCD
1.31
Quick Ratio
CVRX
6.49
LUCD
1.27

Dividends

Dividend Yield
CVRX
--
LUCD
--
Payout Ratio
CVRX
0.0%
LUCD
0.0%

AI Verdict

CVRX BEARISH

CVRX shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.

Strengths
Company has established market presence
Risks
Low profit margin of -94.1%
Weak ROE of -96.6%
LUCD BEARISH

LUCD exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness in profitability, leverage, and operating efficiency. The company suffers from catastrophic operating margins (-931.58%) and negative shareholder equity (P/B of -3.87), suggesting a precarious balance sheet. While revenue growth remains positive at 25.6%, there is a massive disconnect between the fundamental decay and the 'Strong Buy' analyst consensus. The valuation is unjustifiable on a data-driven basis, with a Price/Sales ratio of 46.34 for a company consistently missing earnings estimates.

Strengths
Consistent year-over-year revenue growth of 25.60%
Current ratio of 1.31 provides a minimal short-term liquidity buffer
Strong analyst target price ($4.10) suggesting high speculative potential
Risks
Negative book value (P/B -3.87) indicating liabilities exceed assets
Extreme operating losses with an operating margin of -931.58%
Severe financial health deterioration (Piotroski 1/9)

Compare Another Pair

CVRX vs LUCD: Head-to-Head Comparison

This page compares CVRx, Inc. (CVRX) and Lucid Diagnostics Inc. (LUCD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile